Journal article

The REMEDEE Trial A Randomized Comparison of a Combination Sirolimus-Eluting Endothelial Progenitor Cell Capture Stent With a Paclitaxel-Eluting Stent

Michael Haude, Stephen WL Lee, Stephen G Worthley, Sigmund Silber, Stefan Verheye, Sandra Erbs, Mohd Ali Rosli, Roberto Botelho, Ian Meredith, Kui Hian Sim, Pieter R Stella, Huay-Cheem Tan, Robert Whitbourn, Sukumaran Thambar, Alexandre Abizaid, Tian Hai Koh, Peter Den Heijer, Helen Parise, Ecaterina Cristea, Akiko Maehara Show all

JACC Cardiovascular Interventions | ELSEVIER SCIENCE INC | Published : 2013


OBJECTIVES: This study sought to compare the efficacy and safety results after coronary implantation of a combined sirolimus-eluting CD34 antibody coated Combo stent (OrbusNeich Medical, Ft. Lauderdale, Florida) with the paclitaxel-eluting Taxus Liberté stent (PES) (Boston Scientific, Natick, Massachusetts). This report summarizes the first-in-man randomized, controlled multicenter REMEDEE trial (Randomized study to Evaluate the safety and effectiveness of an abluMinal sirolimus coatED bio-Engineered StEnt) angiographic, intravascular ultrasound, and clinical results up to 12 months. BACKGROUND: Drug-eluting stents have limited restenosis and reintervention but are complicated by especially ..

View full abstract